GlassScriptPhysician profile
Fatima C Stanford
NPI 1598905226
$285,296.91
in general payments reported to CMS, 2019-2025
12 companies · $79K in 2025
The $79K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,009 · 2020: $7,824 · 2021: $32K · 2022: $53K · 2023: $43K · 2024: $63K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $159K · Food and Beverage: $13K · Travel and Lodging: $7,613 · Honoraria: $5,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $159,026.25 |
| Food and Beverage | $12,516.87 |
| Travel and Lodging | $7,612.69 |
| Honoraria | $5,225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $90,555.97 | 2019-2024 | Wegovy |
| Eli Lilly and Company | $82,909.16 | 2021-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31,143.88 | 2021-2025 | |
| Amgen INC. | $25,704.65 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $24,978.53 | 2021-2025 | Contrave |
| Novo Nordisk As | $8,100.00 | 2023-2024 | |
| Lilly USA, LLC | $6,174.62 | 2023 | Mounjaro |
| Azurity Pharmaceuticals, INC. | $5,225.00 | 2025 | |
| Zimmer Biomet Holdings, INC. | $4,330.10 | 2019-2020 | |
| Abbvie INC. | $3,875.00 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $1,800.00 | 2021 | |
| Pfizer INC. | $500.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Stanford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.